Browse Prior Art Database

Solid State Forms of N-[(9S,10R,11R,13R)-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-11-yl]-N-methylbenzamide

IP.com Disclosure Number: IPCOM000250563D
Publication Date: 2017-Aug-03

Publishing Venue

The IP.com Prior Art Database

This text was extracted from a PDF file.
This is the abbreviated version, containing approximately 21% of the total text.

1

Solid State Forms of N-[(9S,10R,11R,13R)-2,3,10,11,12,13-Hexahydro-10-methoxy-9-

methyl-1-oxo-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-

j][1,7]benzodiazonin-11-yl]-N-methylbenzamide

Described herein are crystalline forms of N-[(9S,10R,11R,13R)-2,3,10,11,12,13-Hexahydro-10-

methoxy-9-methyl-1-oxo-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-

j][1,7]benzodiazonin-11-yl]-N-methylbenzamide, referred herein as Compound I.

Samples of Compound I were prepared by the processes described in examples 1-15, and were

analyzed by X-ray powder diffraction ("XRPD") to provide the below crystalline forms.

Figures 1- 15 present the XRPD of the obtained forms.

Figure 1: An X-ray powder diffractogram of amorphous Compound I

2

Figure 2: An X-ray powder diffractogram of Form V of Compound I

The crystalline Form V of Compound I can be characterized by PXRD peak list as shown in

table 1.

Table 1:

peak position (degrees two theta

± 0.2 degrees two-theta)

6.2

8.1

9.8

12.5

13.2

13.6

14.5

16.2

16.8

17.7

18.2

18.6

19.2

19.7

22.5

25.0

25.8

26.1

3

Figure 3: An X-ray powder diffractogram of Form VI of Compound I

The crystalline Form VI of Compound I can be characterized by PXRD peak list as shown in

table 2.

Table 2:

peak position (degrees two theta

± 0.2 degrees two-theta)

6.8

7.5

9.5

11.0

12.5

12.9

13.7

14.2

14.7

15.0

16.1

17.3

18.4

19.9

20.4

21.2

22.3

23.0

23.7

24.5

25.0

26.1

26.9

27.8

28.7

29.7

4

30.4

32.1

Figure 4: An X-ray powder diffractogram of Form VII of Compound I

The crystalline Form VII of Compound I can be characterized by PXRD peak as shown in table

3.

Table 3:

peak position (degrees two theta

± 0.2 degrees two-theta)

4.3

6.8

7.5

8.5

9.1

10.7

13.1

14.0

14.6

15.1

15.5

16.1

17.5

18.2

18.6

18.8

19.6

20.6

21.0

21.6

22.3

5

22.7

23.5

24.3

25.1

26.7

27.5

Figure 5: An X-ray powder diffractogram of Form VIII of Compound I

The crystalline Form VIII of Compound I can be characterized by PXRD peak list as shown in

table 4.

Table 4:

peak position (degrees two theta

± 0.2 degrees two-theta)

6.0

6.6

8.3

9.1

9.6

10.0

10.8

11.6

12.1

13.0

13.7

14.0

14.6

15.6

16.0

16.5

17.8

18.2

19.3

6

19.7

20.1

20.9

21.4

21.8

22.5

23.2

23.5

24.0

24.5

24.8

25.2

25.8

26.8

27.1

27.8

28.2

28.7

30.4

30.9

31.5

32.4

33.2

Figure 6: An X-ray powder diffractogram of Form IX of Compound I

The crystalline Form IX of Compound I can be characterized by PXRD peak list as shown in

table 5.

Table 5:

peak position (degrees two theta

± 0.2 degrees two-theta)

6.3

7

8.1

9.9

11.6

11.9

12.6

13.3

13.7

14.6

16.3

17.0

17.8

18.4

18.8

19.4

20.0

20.6

22.8

23.7

24.0

24.6

25.2

26.1

26.9

27.6

28.0

28.5

29.0

30.2

31.3

31.8

32.4

32.8

34.0

35.6

8

Figure 7: An X-ray powder diffractogram of Form X of Compound I

The crystalline Form X of Compound I can be characterized by PXRD peak list as shown in

table 6.

Table 6:

peak position (degrees two theta

± 0.2 degrees two-theta)

6.3

7.9

9.9

11.9

12.6

13.4

14.4

15.9

17.6

18.4

19.0

19.6

19.9

20.5

21.9

22.5

22.8

23.4

23.8

24.1

24.7

25.9

26.9

30.2

30.9

9

F...